CSIMarket
 


Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 
 

SYRS's Capital Expenditures Growth by Quarter and Year

Syros Pharmaceuticals Inc 's Capital Expenditures results by quarter and year




SYRS Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.67 0.25 0.03
III Quarter September 0.00 0.33 0.31 0.52
II Quarter June 0.00 0.11 0.43 0.99
I Quarter March 0.24 0.13 0.26 1.80
FY   0.24 1.24 1.25 3.34



SYRS Capital Expenditures third quarter 2023 Y/Y Growth Comment
Syros Pharmaceuticals Inc in the third quarter 2023 recorded Capital Expenditures of $ 0.00 millions.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 55 other companies have achieved higher Capital Expenditures growth. While Syros Pharmaceuticals Inc ' s Capital Expenditures no change of % ranks overall at the positon no. 1138 in the third quarter 2023.




SYRS Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 168 % 733.33 % -99.63 %
III Quarter September - 6.45 % -40.38 % -79.77 %
II Quarter June - -74.42 % -56.57 % -25 %
I Quarter March 84.62 % -50 % -85.56 % 205.08 %
FY   - -0.8 % -62.57 % -73.58 %

Financial Statements
Syros Pharmaceuticals Inc 's third quarter 2023 Capital Expenditures $ 0.00 millions SYRS's Income Statement
Syros Pharmaceuticals Inc 's third quarter 2022 Capital Expenditures $ 0.33 millions Quarterly SYRS's Income Statement
New: More SYRS's historic Capital Expenditures Growth >>


SYRS Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 103.03 % -19.35 % -94.23 %
III Quarter September - 200 % -27.91 % -47.47 %
II Quarter June - -15.38 % 65.38 % -45 %
I Quarter March -64.18 % -48 % 766.67 % -77.94 %
FY (Year on Year)   - -0.8 % -62.57 % -73.58 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #56
Healthcare Sector #154
Overall #1138

Capital Expenditures Y/Y Growth Statistics
High Average Low
1012.81 % 168.89 % -91.02 %
(Jun 30 2019)   (Sep 30 2021)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #56
Healthcare Sector #154
Overall #1138
Capital Expenditures Y/Y Growth Statistics
High Average Low
1012.81 % 168.89 % -91.02 %
(Jun 30 2019)   (Sep 30 2021)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Syros Pharmaceuticals Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SYRS's III. Quarter Q/Q Capital Expenditures Comment


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SYRS's III. Quarter Q/Q Capital Expenditures Comment


Syros Pharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 1.35 $ 1.24 $ 0.81
Y / Y Capital Expenditures Growth (TTM) - - 21.33 % -0.32 % -21.09 %
Year on Year Capital Expenditures Growth Overall Ranking # 1536 # 1231 # 1446 # 1809 # 1895
Seqeuential Capital Expenditures Change (TTM) - - 8.62 % 52.83 % 2.27 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1138 # 1183 # 1202 # 883 # 1463




Cumulative Capital Expenditures growth Comment
Syros Pharmaceuticals Inc realized trailing twelve months Capital Expenditures of $ 0 millions, in the Sep 30 2023, compare to Capital Expenditures of $ 1 millions a year ago.

In the Healthcare sector 221 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1231 to 1536.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1012.81 %
168.89 %
-91.02 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 56
Healthcare Sector # 222
Overall # 1536

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1012.81 %
168.89 %
-91.02 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 56
Sector # 154
S&P 500 # 1138
Cumulative Capital Expenditures growth Comment
Syros Pharmaceuticals Inc realized trailing twelve months Capital Expenditures of $ 0 millions, in the Sep 30 2023, compare to Capital Expenditures of $ 1 millions a year ago.

In the Healthcare sector 221 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1231 to 1536.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1012.81 %
168.89 %
-91.02 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 56
Healthcare Sector # 222
Overall # 1536

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1012.81 %
168.89 %
-91.02 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 56
Sector # 154
S&P 500 # 1138




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
SYRS's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for SYRS's Competitors
Capital Expenditures Growth for Syros Pharmaceuticals Inc 's Suppliers
Capital Expenditures Growth for SYRS's Customers

You may also want to know
SYRS's Annual Growth Rates SYRS's Profitability Ratios SYRS's Asset Turnover Ratio SYRS's Dividend Growth
SYRS's Roe SYRS's Valuation Ratios SYRS's Financial Strength Ratios SYRS's Dividend Payout Ratio
SYRS's Roa SYRS's Inventory Turnover Ratio SYRS's Growth Rates SYRS's Dividend Comparisons



Companies with similar Capital Expenditures no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen Inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com